Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling.
about
Erectile dysfunction in heart failure patients: a critical reappraisalTherapeutic potential of PDE modulation in treating heart diseaseProtection by the NO-Donor SNAP and BNP against Hypoxia/Reoxygenation in Rat Engineered Heart TissuePhosphodiesterases and cardiac cGMP: evolving roles and controversiesPriming the proteasome by protein kinase G: a novel cardioprotective mechanism of sildenafilAmbient particulates alter vascular function through induction of reactive oxygen and nitrogen speciesSirtuin 1 (SIRT1) activation mediates sildenafil induced delayed cardioprotection against ischemia-reperfusion injury in miceMetformin protects cardiomyocyte from doxorubicin induced cytotoxicity through an AMP-activated protein kinase dependent signaling pathway: an in vitro studyPretreatment of sildenafil attenuates ischemia-reperfusion renal injury in ratsMitofusin-2 maintains mitochondrial structure and contributes to stress-induced permeability transition in cardiac myocytes.Role of phosphodiesterase-5 inhibitors in heart failure: emerging data and concepts.Fiber type-specific nitric oxide protects oxidative myofibers against cachectic stimuliPivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts.RAGE modulates hypoxia/reoxygenation injury in adult murine cardiomyocytes via JNK and GSK-3beta signaling pathways.Chronic inhibition of phosphodiesterase 5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: potential role of NO/SIRT1/PGC-1α signaling.Cardiomyocyte S1P1 receptor-mediated extracellular signal-related kinase signaling and desensitizationPDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells.Differential regulation of PDE5 expression in left and right ventricles of feline hypertrophy models.Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects.Phosphodiesterase-5 inhibition mimics intermittent reoxygenation and improves cardioprotection in the hypoxic myocardium.Phospholemman Ser69 phosphorylation contributes to sildenafil-induced cardioprotection against reperfusion injury.Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts.Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction.Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.Shen-Fu injection preconditioning inhibits myocardial ischemia-reperfusion injury in diabetic rats: activation of eNOS via the PI3K/Akt pathwayAnti-inflammatory and cardioprotective effects of tadalafil in diabetic miceAdenosine A(1) receptor mediates delayed cardioprotective effect of sildenafil in mouse.Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase g-dependent generation of hydrogen sulfideDevelopment of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases.Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbitsAttenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil: A Long Acting Phosphodiesterase-5 Inhibitor.Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathwayThe role of phosphodiesterase inhibitors in the management of pulmonary vascular diseasesMitochondrial vulnerability and increased susceptibility to nutrient-induced cytotoxicity in fibroblasts from leigh syndrome French canadian patients.Enhanced autophagy from chronic toxicity of iron and mutant A53T α-synuclein: implications for neuronal cell death in Parkinson diseaseEmerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.Tadalafil Integrates Nitric Oxide-Hydrogen Sulfide Signaling to Inhibit High Glucose-induced Matrix Protein Synthesis in PodocytesInteraction between leucine and phosphodiesterase 5 inhibition in modulating insulin sensitivity and lipid metabolismDifferential expression of PDE5 in failing and nonfailing human myocardium
P2860
Q26853624-776376CC-E8C7-4C04-90F6-690BFC6CD341Q27005761-F488263C-31AA-4B12-8DE8-B41B8927C9A2Q27303065-4917816F-81D4-455B-995D-C639FD031C36Q27692588-D3EDC030-14C4-4DB9-927D-79856CF4B42CQ28084015-ECA1D2C9-9440-4945-BBD7-693DCC54D470Q28390268-DF273DB6-F167-4808-85BF-C893CA65C364Q28539039-538E4D08-EC58-4A78-9B36-890EBC817803Q28541996-F9B0AF29-FE04-4677-8C08-5C599CA83AC3Q28581703-E7CFCCEB-B3C5-4FC1-8394-6B4C93962262Q30499251-1E44C33B-238A-4539-9E7D-65D3871C23D8Q30575578-20E094B5-F530-4A8A-BBC9-EEF46A6F2299Q33332170-B692A59B-31E5-44EB-8C95-26093A28517DQ33552229-97DAEEA2-D87B-46AE-A844-E08774BAF6FBQ33559727-608D6200-0E1A-4AE0-B886-3ABE5F7FE952Q33701938-88CF6433-5DF5-43DF-B573-ACEB2BB5534CQ33715382-8FF09CB2-F355-4C43-95BF-28D729219ACDQ33727865-B9D68CA5-D184-4E79-8FC6-5D463BFF4278Q33916555-686FD6AD-7ADD-4993-AFDE-B34D1EEA260CQ33966155-BF7081B8-38EE-4CF1-8755-1D7F3DF9F76BQ34091110-9FDAF863-F208-45B7-AE0B-07CCC255D7B8Q34150566-5C089CDA-E573-41C2-8873-307C91D8536AQ34152435-2E273F5D-9E07-455D-94E1-FA686E5D272EQ34241307-6388A2B8-A5E2-4098-A33A-587057DD9510Q34252901-0E333C18-1F90-40F6-A7ED-33AFC40D377AQ34277031-0FC56B60-5D83-455E-AB33-56FB7E8943B8Q34382922-2BECA68A-F2DC-4F46-9BC0-3E5B2744598DQ34428464-43F9C134-F517-4600-A495-0B516556A3D9Q34503360-D0490549-AB04-4953-9193-8692D0B553A7Q34503391-D367B287-2EAC-4F63-8B4B-F54CE164DF70Q34538482-3DE7D369-5ADA-4339-A719-DC859CD2FD96Q34543457-D19C48F1-1DC8-402E-8B9D-F333746C391DQ34793299-1789C1D6-9554-4F78-AEB6-0C7BE6682E0CQ35056906-740AA5FB-9F8F-4D73-B799-4EE21D622280Q35156618-14E1F51A-A943-4AC6-890D-1E6AFDB0E64DQ35250813-001A1F4C-96DD-45FA-93E5-BFE8C9D9BF93Q35312446-754B831C-55B7-438C-9C37-ACC9CC4C5E06Q35500693-98347DB0-B620-4E4D-8856-2531C1A51197Q35583071-9FDBD993-0E8A-4F54-8EEC-17F9DF6B4274Q35592315-6BB4D9A6-857B-4945-94C5-152AB1DFB5B2Q35680934-AC5B5647-C017-4D00-8793-2D50305EF38B
P2860
Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Phosphodiesterase-5 inhibitor ...... ole of nitric oxide signaling.
@en
Phosphodiesterase-5 inhibitor ...... ole of nitric oxide signaling.
@nl
type
label
Phosphodiesterase-5 inhibitor ...... ole of nitric oxide signaling.
@en
Phosphodiesterase-5 inhibitor ...... ole of nitric oxide signaling.
@nl
prefLabel
Phosphodiesterase-5 inhibitor ...... ole of nitric oxide signaling.
@en
Phosphodiesterase-5 inhibitor ...... ole of nitric oxide signaling.
@nl
P2860
P356
P1476
Phosphodiesterase-5 inhibitor ...... role of nitric oxide signaling
@en
P2093
Rakesh C Kukreja
P2860
P304
12944-12955
P356
10.1074/JBC.M404706200
P407
P577
2005-01-24T00:00:00Z